Literature DB >> 31337604

Alliance of the Titans: An Effective Combination of a TKI with CAR T Cells.

Andras Heczey1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31337604      PMCID： PMC6698246          DOI： 10.1016/j.ymthe.2019.07.008

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

1.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Mark E Dudley; Sadik H Kassim; Robert P T Somerville; Robert O Carpenter; Maryalice Stetler-Stevenson; James C Yang; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; Mark Raffeld; Steven Feldman; Lily Lu; Yong F Li; Lien T Ngo; Andre Goy; Tatyana Feldman; David E Spaner; Michael L Wang; Clara C Chen; Sarah M Kranick; Avindra Nath; Debbie-Ann N Nathan; Kathleen E Morton; Mary Ann Toomey; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 2.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

3.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

4.  Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.

Authors:  Xiuqi Wu; Hong Luo; Bizhi Shi; Shengmeng Di; Ruixin Sun; Jingwen Su; Ying Liu; Hua Li; Hua Jiang; Zonghai Li
Journal:  Mol Ther       Date:  2019-04-29       Impact factor: 11.454

5.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.

Authors:  Itay Tirosh; Benjamin Izar; Sanjay M Prakadan; Marc H Wadsworth; Daniel Treacy; John J Trombetta; Asaf Rotem; Christopher Rodman; Christine Lian; George Murphy; Mohammad Fallahi-Sichani; Ken Dutton-Regester; Jia-Ren Lin; Ofir Cohen; Parin Shah; Diana Lu; Alex S Genshaft; Travis K Hughes; Carly G K Ziegler; Samuel W Kazer; Aleth Gaillard; Kellie E Kolb; Alexandra-Chloé Villani; Cory M Johannessen; Aleksandr Y Andreev; Eliezer M Van Allen; Monica Bertagnolli; Peter K Sorger; Ryan J Sullivan; Keith T Flaherty; Dennie T Frederick; Judit Jané-Valbuena; Charles H Yoon; Orit Rozenblatt-Rosen; Alex K Shalek; Aviv Regev; Levi A Garraway
Journal:  Science       Date:  2016-04-08       Impact factor: 47.728

6.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 8.  Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.

Authors:  Jorge Filmus; Mariana Capurro
Journal:  FEBS J       Date:  2013-01-31       Impact factor: 5.542

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.

Authors:  Yu Sawada; Toshiaki Yoshikawa; Daisuke Nobuoka; Hirofumi Shirakawa; Toshimitsu Kuronuma; Yutaka Motomura; Shoichi Mizuno; Hiroshi Ishii; Kohei Nakachi; Masaru Konishi; Toshio Nakagohri; Shinichiro Takahashi; Naoto Gotohda; Tadatoshi Takayama; Kenji Yamao; Katsuhiko Uesaka; Junji Furuse; Taira Kinoshita; Tetsuya Nakatsura
Journal:  Clin Cancer Res       Date:  2012-05-10       Impact factor: 12.531
View more
  1 in total

Review 1.  Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?

Authors:  Yeison Santamaria-Alza; Gloria Vasquez
Journal:  Inflamm Res       Date:  2021-05-20       Impact factor: 4.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.